Overview
Updated 14 Jul 2026
Don S. Dizon, MD, is System Chief of Hematology-Oncology, Tufts Medicine. The public record shows 509 publications with 11,747 citations (h-index 58), centered on Breast Cancer, Ovarian / Gynecologic Cancer, Prostate Cancer. It also documents an investigator role on 20 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2020–2020).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Breast Cancer
- 20 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 38 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industrytrials, payments and federal funding
Public positionssourced statements on record
- Editor
CA: A Cancer Journal for Clinicians (American Cancer Society flagship journal), effective April 1
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pressroom.cancer.org ↗ - Vice Chair of Membership and Accrual
SWOG Cancer Research Network
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tuftsmedicine.org ↗
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 20 registered studies on ClinicalTrials.gov. The most recent:
- E-Mindfulness Approaches for Living After Breast Cancer
Sponsor: NRG Oncology
InvestigatorPhase 3RecruitingNCT06748222 - Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 3RecruitingNCT06058377 - Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
Sponsor: NRG Oncology
InvestigatorRecruitingNCT05896189
Industry payments
Updated 14 Jul 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- TerSera Therapeutics LLCProgram year20257 payments
- Stemline Therapeutics Inc.Program year20251 payment
- AstraZeneca UK LimitedProgram year20251 payment
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2020–2020 per NIH RePORTER. The latest:
- The Collaboration for Outcomes using Social Media in Oncology (COSMO) Conference
Rhode Island Hospital
FY2020$10,000R13CA239613
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Menopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibition.
Journal of clinical oncology
2026 - CA turns 75: Looking at the future but never forgetting the roots.
CA: a cancer journal for clinicians
2025
Contact
No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.brown.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.brown.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.brown.edu ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vivo.brown.edu ↗
Editorial & leadership rolesjournal and society appointments
- System Chief of Hematology-Oncology
Tufts Medicine cancer service line
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancerletter.com ↗ - Jane F. Desforges
MD, Endowed Chair in Hematology and Oncology, Tufts University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Professor of Medicine
Tufts University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tuftsmedicine.org ↗
Awards & honorshonors on the public record
- Excellence in Equity Award
American Society of Clinical Oncology (endowed by the American Cancer Society), 2025 ASCO Annual Meeting
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.brown.edu ↗
Secondary affiliationsappointments beyond the home institution
- Formerly Professor of Medicine and Professor of Surgery
Warren Alpert Medical School of Brown University; Lifespan Cancer Institute / Legorreta Cancer Center, Providence, RI
2025provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →brownhealth.org ↗
Media & interviewspress, podcasts and appearances
- Video commentary
"Don S. Dizon on Ovarian and Other Extrarenal Clear Cell Carcinomas Update on Nivolumab and Ipilimumab," The ASCO Post
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Host
"Your Stories: Conquering Cancer" podcast, Conquer Cancer (the ASCO Foundation)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →conquer.org ↗ - "Get to Know Don S. Dizon, MD, FACP, FASCO, System Chief of Hematology-Oncology"
Tufts Medicine video feature
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Facebook
facebook.com/drdonstevendizon
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/drdonsdizon
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - LinkedIn
linkedin.com/in/donsdizonmd
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗
Mentions by otherswhere others cite or feature them
- Other
healio.com/news/hematology-oncology/podcasts/oncology-overdrive/episode-120
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - Tiktok.com
TikTok: @drdonsdizon ("DoctorDon"), oncology and social-media-in-medicine commentary
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tiktok.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
James Udelson, MD
Tufts Medical Center
- 549
- publications
- 102
- h-index
- 8
- trials
Nicholas Hill, MD
Tufts Medical Center
- 640
- publications
- 77
- h-index
- 19
- trials
Carey Kimmelstiel, MD
Tufts Medical Center
- 192
- publications
- 37
- h-index
- 2
- trials
David Rosmarin, MD
Tufts Medical Center
- 229
- publications
- 36
- h-index
- 6
- trials